Outcomes of AF Ablation

Similar documents
Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.

A Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC

Debate-STAR AF 2 study. PVI is not enough

Atrial Fibrillation Ablation: in Whom and How

Long Standing Persistent AF ; CPVI is enough for it

Atrial Fibrillation: Catheter Ablation with New Technologies, Improving Quality of Life and Outcomes in Various Disease States

Catheter ablation of atrial fibrillation: Indications and tools for improvement of the success rate of the method. Konstantinos P.

Catheter Ablation for Atrial Fibrillation: Patient Selection and Outcomes

Fibrillation Atriale Paroxystique : ablation, résultats, complications

Contemporary Strategies for Catheter Ablation of Atrial Fibrillation

What s new in my specialty?

Recent observations have focused attention on the PVs as a source of ectopic activity i determining i AF

Is cardioversion old hat? What is new in interventional treatment of AF symptoms?

Atrial Fibrillation Ablation in Patients with Heart Failure

AF Ablation in 2015 Why, Who, What and How? Steve Wilton ACC Rockies, Banff March 10, 2015

How Should we Select Patients for Catheter Ablation? Douglas Esberg, MD, FHRS

ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital

AF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire

Interventional solutions for atrial fibrillation in patients with heart failure

Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD

Role of LAA isolation in AF cure

Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015

Atrial Fibrillation Ablation in Patients with Heart Failure

Combined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation

In Whom and When Should Atrial Fibrillation Ablation be Considered?

Jesus M. Paylos, C. Ferrero, L. Azcona, A. Morales, M. A. Vargas, L. Lacal, V. Gomez Tello.

Atrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology

The EP Perspective: Should We Do Hybrid Ablation, and Who Should We Do It On?

Catheter ablation of AF Where do we stand, where do we go?

Atrial fibrillation and advanced age

Long-Term Outcome and Risks of Catheter Ablation for Atrial Fibrillation

Διαδερμική Θεραπεία Κολπικής Μαρμαρυγής: Αποτελέσματα και Δεδομένα στην Ελλάδα

Storia dell ablazione della fibrillazione atriale: da dove siamo partiti, dove siamo, dove andremo. Prof. Fiorenzo Gaita

Indicatie voor ablatie bij voorkamerfibrillatie. Andrea Sarkozy Cardiologie Universitair Ziekenhuis Antwerpen

Ablation of persistent AF Is it different than paroxysmal?

Pulmonary Vein Isolation for AF RF or Cryo? Dr. Yuen Ho Chuen Princess Margaret Hospital

Individualised strategy approach to AF ablation

Innovations in AF Management

FA et Apnée du Sommeil

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation

Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial

Rebuttal. Jerónimo Farré MD 2010

PVI and What Else for Persistent AF Lessons Learned from STAR AF 2 CCCEP 2015 October 31, New York

Treatment of Atrial Fibrillation in Heart Failure

Surgical Ablation for Lone AF: What have we learned after 30 years?

עדכונים באלקטרופיזיולוגיה Electrophysiology Unit Soroka University Medical Center Faculty of Health Sciences Ben-Gurion University of the Negev

UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate

Rate and Rhythm Control of Atrial Fibrillation

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

AF ABLATION Concepts and Techniques

Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice

Raphael Rosso MD, Yuval Levi Med. Eng., Sami Viskin MD Tel Aviv Sourasky Medical Center

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation

Linear Ablation Should Not Be a Standard Part of Ablation in Persistent AF. Disclosures. LA Ablation vs. Segmental Ostial Ablation With PVI for PAF

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?

Catheter ablation in AF patients with heart failure. What is possible?

SEVEN YEARS OF CRYO-BALLOON CATHETER ABLATION

CLINICAL COMPENDIUM. The HeartLight Endoscopic Ablation System Putting a New Level of PVI Precision Close at Hand. CardioFocus.com

심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation

Atrial Fibrillation and Heart Failure: Rate vs. Rhythm Control Time for Re-evaluation

Catheter Ablation of Atrial Fibrillation Persistent Atrial Fibrillation Catheter Ablation : where are we?

Ablazione della fibrillazione atriale: dubbi presenti e prospettive future

Catheter Ablation for Persistent Atrial Fibrillation

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

High density substrate mapping In AF

AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT

علم االنسان ما لم يعلم

Μηνύματα από τις σπουδαιότερες μελέτες στην ηλεκτροφυσιολογία το διάστημα

480 April 2004 PACE, Vol. 27

Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK

CARDIOINSIGHT TM NONINVASIVE 3D MAPPING SYSTEM CLINICAL EVIDENCE SUMMARY

ESC Stockholm Arrhythmias & pacing

Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh

Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it?

Are Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist

Long-Term ECG Monitoring Using an ILR. Evgeny Pokushalov, MD, PhD

Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation Executive Summary

Percutaneous Transvenous Atrial Fibrillation Ablation and Stroke

CLINICAL COMPENDIUM. The HeartLight Endoscopic Ablation System Putting a New Level of PVI Precision Close at Hand. CardioFocus.com

Fibrillazione atriale e scompenso: come interrompere il circolo vizioso.

Long-Term Atrial Fibrillation Progression: What We Know in 2014

Surgical Ablation: Which Lesion Set for Which Patient?

Atrial Fibrillation and Sleep Apnea. Farhat S. Khairallah, MD, FHRS, FACC

Atrial Fibrillation What are the Options in 2016?

Cardiac Imaging in abnormal rhythm Role of MDCT

National Medical Policy

CLINICAL OUTCOME OF AF ABLATION Who Benefits from Catheter Ablation?? Dr Gamal Shaban MD FESC Fellow of EHRA ECR AFA AFIB ALLIANCE NHI

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

Controversies in Atrial Fibrillation and HF

Supplementary Online Content

Catheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF?

What s New in the Guidelines for Surgical Ablation for Atrial Fibrillation?

Catheter Ablation of Atrial Fibrillation

Watchman Implantation Case Presentation and Discussion

University of Groningen. Ablation of atrial fibrillation de Maat, Gijs Eduard

When does enhanced monitoring for atrial fibrillation add value?

ATRIAL FIBRILLATION: IS IT REALLY TYPE 2 DIABETES MASQUERADING AS CARDIAC MISFORTUNE?

Role of Ablation of AF and PVCs in the Management of Heart Failure

Transcription:

2017 춘계심혈관통합학술대회 AF Summit: Atrial Fibrillation Apr.21(Fri) 14:40-16:10 Rm.300B 15:00-15:10 Outcomes of AF Ablation Gi-Byoung Nam MD Asan Medical Center, UUCM 2017 Annual Spring Scientific Conference of the KSC in conjunction with KHRS, KSIC, KSE, and KSoLA

The Korean Society of Cardiology COI Disclosure Name of First Author: Gi-Byoung Nam MD The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific Conference of the KSC in conjunction with KHRS, KSIC, KSE, and KSoLA

Evolution of Ablation Strategy Atrial Fibrillation Ablation: Reaching the Mainstream JOHN D. FISHER, PACE 2006; 29:523 537

Comparative Effectiveness of Wide Antral Versus Ostial Pulmonary Vein Isolation Circ Arrhythm Electrophysiol 2014;7:39-45

Benefits and risks of additional ablation of CFE in paf S. Wu et al. / International Journal of Cardiology 169 (2013) 35 43

Is there still a role for additional linear ablation in patients with paf? An Updated Meta-analysis of RCTs * sinus rhythm maintenance * risks for complications International Journal of Cardiology 209 (2016) 266 274

Comparison with AAD Among patients with paroxysmal AF who had not responded to at least 1 antiarrhythmic drug, the use of catheter ablation compared with ADT resulted in a longer time to treatment failure during the 9-month followup period. JAMA. 2010;303(4):333-340

Long-term Outcomes of Catheter Ablation of AF : A Systematic Review and Meta-analysis J Am Heart Assoc. 2013;2:e004549

Procedure Success: meta analysis 12 month single procedure Late outcome single procedure Late multiple procedure paf 66.6% (95% CI: 58.2%-74.2%) 54.1% (95% CI:44.463.4%) 79.0% (95% CI: 67.6%-87.1%) NPAF 51.9% (95% CI: 33.8%- 69.5%) 41.8% (95% CI: 25.2-60.5%) 77.8% (95% CI: 68.7-84.9%) (1) a single ablation procedure may be sufficient to achieve freedom from atrial arrhythmia in 50% of patients, (2) multiple procedures will be required to achieve control of AF in many patients, but 80% of patients will achieve long-term freedom from atrial arrhythmia; and (3) Although there is an incidence of late recurrence in initially successfully ablated patients, there is relative stability of arrhythmia-free survival at late-term follow-up of 5 years. J Am Heart Assoc. 2013;2:e004549

Discerning the Incidence of Sx and Asx Episodes of AF Before and After Catheter Ablation (DISCERN AF) Before and after ablation, a greater proportion of AF/AFL/AT duration was asymptomatic. In total, 69.0% of all episodes, or 56.0% of the total AF/AFL/AT duration, were considered asymptomatic. Atrial arrhythmia burden decreased by 86%, from 2.0 to 0.3 hrs/pt/day. Episodes of AF became shorter from a median of 22 to 6 minutes, less irregular, and more likely to be asymptomatic (from 52% before to 79% after ablation; P=.002). The success rate of AF ablation: 58% by Sx, 46% w ILR at 18 months. (Six patients (12%) exclusively ASx recurrences) JAMA Intern Med. 2013;173(2):149-156

Catheter Ablation Versus AAD Therapy for AF (CABANA) Trial catheter ablation vs. current pharmacologic therapy (either rate control or rhythm control drugs) primary endpoint - total mortality secondary endpoint - composite endpoint of total mortality, disabling stroke, serious bleeding and cardiac arrest. Additional secondary endpoints will include AF recurrence and quality of life and cost effectiveness. The EAST (Early treatment of AF for Stroke prevention Trial) recent onset AF at risk for stroke (CHA₂DS₂VASc score 2) guideline-mandated usual care (anticoagulation, therapy of underlying heart disease, and rate control) or to usual care plus early rhythm control therapy (antiarrhythmic drugs, catheter ablation) primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction. secondary outcomes include cognitive function and quality of life.

Durable PVI Simple PVI Adenosine Pacing Contact force Cryo-balloon Laser-balloon Hot-balloon PVAC-gold

Adenosine-guided PV isolation for the Tx of paf : ADVICE trial Adenosine unmasked dormant PV conduction in 284/534 pts (53%). Additional adenosine-guided ablation - an absolute risk reduction of 27 1% and a hazard ratio of 0 44 (95% CI 0 31 0 64; p<0 0001). Occurrences of serious adverse events were similar in each group. Conclusion: Adenosine testing to identify and target dormant PV conduction during catheter ablation of AF is a safe and highly effective strategy to improve arrhythmia-free survival in patients with paf. This approach should be considered for incorporation into routine clinical practice. Lancet 2015; 386: 672 79

paf Catheter Ablation with a CF Sensing Catheter Results of the Prospective, Multicenter SMART-AF Trial J Am Coll Cardiol 2014;64:647 56

Cryoballoon or RF Ablation for Paroxysmal AF Cryoballoon ablation was noninferior to RF ablation with respect to efficacy for the Tx of patients with paf, and there was no significant difference between the 2 methods with regard to overall safety.

Persistent AF

Approaches to Catheter Ablation for Persistent AF N Engl J Med 2015;372:1812-22.

The impact of adjunctive CFE ablation and linear lesions on outcomes in persistent AF: a meta-analysis Europace (2016) 18, 359 367

PVI vs stepwise approach: CHASE AF trial J Am Coll Cardiol 2015;66:2743 52 A stepwise approach aimed at AF termination does not seem to provide additional benefit over PVI alone in patients with peaf, but it is associated with significantly longer procedural and fluoroscopic duration as well as RF application time.

Anatomical Functional Thoracic vein (PW, CS, VoM, SVC) LA Appendage CFE mcfe FIRM LA scar Common target? Individualized?

paf PeAF LS PeAF Trigger(PV) Substrate https://www.google.co.kr/search?q=elephant+blind+man+story&tbm=isch &imgil=ozqeg2iwx6qrnm%253a%253bmkurxxelorkv7m%253bhttp%252 53A%25252F%25252Fwww.philipchircop.com%25252Fpost%25252F2578327 5888%25252Fseeing-the-full-elephant-its-a-tree-itsa&source=iu&pf=m&fir=ozQEG2iwX6qRNM%253A%252CMKURXxelorKV7 M%252C_&usg= W1DIInuZ2COOunlDhNXW1IRxXO0%3D&biw=1423&bih =696&ved=0ahUKEwi8ruWXo6vTAhUBN5QKHdaYCbkQyjcIPQ&ei=6Zf0WPy VCYHu0ATWsabICw#imgrc=V9yW51ShYcj1UM:&spf=25

Conclusions 1. 심방세동의도자절제술은동율동조절에있어약물치료보다우월한효과. 2. 3년이상의장기효과는단일시술시 50%, 반복시술시약 80% 효과. 3. 발작성심방세동은폐정맥주위심근고립술로 ( 완벽하지는않으나 ) 어느정도만족스러운결과. 4. 재발의주요원인이불완전한폐정맥고립술에기인한다는점에서좀더완벽한폐정맥고립술을이루기위한방법으로연구가진행되고있으며, 동시에폐정맥고립술을더욱간편하게수행하기위한연구도진행중. 5. 지속성심방세동에서는폐정맥고립술만으로는부족하나, 추가시술의효과가정립되지않음.